Molecular Microsensors in The Digestive Tract Cancer: Circulating MicroRNAs_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

 JIANGChao ,  WANGQiong , XUZhe

Department of Digestive Tumors Surgery, Traditional Chinese Medicine Hospital of Jiangsu Province, Nanjing 210029, Jiangsu Province, China;

Corresponding author：

WANGQiong, Email: calcspar@163.com

Keywords：

Circulating microRNAs; digestive tract cancer; Biomarker of tumor

DOI：

10.7507/1007-9424.20150098

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the relationship between microRNAs (miRNAs) and the digestive tract cancer, and to investigate the applicative value of miRNAs in the diagnosis, treatment, and prognosis evaluation of the digestive tract cancer. Methods Domestic and international papers focusing on the relationship between miRNAs and the digestive tract cancer were retrieved and reviewed. Results miRNAs participated in cell proliferation, differentiation, and apoptosis through gene regulation. The patients with digestive tract cancer were often accompanied with some abnormal expression of miRNAs in circulation, that was closely related to the occurrence and development of tumor. These miRNAs in blood contributed to not only the diagnosis of tumor, but also identification of the primary tumor site, even the clinical and pathological staging. Thus, we could predict the progress, recurrence, and the metastasis of tumor, or perform the evaluation of therapeutic effects. Conclusion Circulating miRNAs can be used as molecular microsensors for the noninvasive early diagnosis, treatment, and prognosis of the digestive tract cancer.

Citation： JIANGChao, WANGQiong, XUZhe. Molecular Microsensors in The Digestive Tract Cancer: Circulating MicroRNAs. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2015, 22(3): 365-368. doi: 10.7507/1007-9424.20150098 Copy

1.	Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
2.	Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer:a systematic review. Cancer Epidemiol Biomarkers Prev, 2007, 16(10):1935-1953.
3.	Brennecke J, Stark A, Russell RB, et al. Principles of microRNA-target recognition. PLoS Biol, 2005, 3(3):e85.
4.	Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120(1):15-20.
5.	Marson A, Levine SS, Cole MF, et al. Connecting miRNAs genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell, 2008, 134(3):521-533.
6.	Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 2008, 141(5):672-675.
7.	Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008, 105(30):10513-10518.
8.	Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 2008, 18(10):997-1006.
9.	Mittra I, Nair NK, Mishra PK. Nucleic acids in circulation: are they harmful to the host?. J Biosci, 2012, 37(2):301-312.
10.	Liang Y, Ridzon D, Wong L, et al. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics, 2007, 8:166.
11.	Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature, 2005, 435(7043):834-838.
12.	Ma R, Jiang T, Kang XX. Circulating microRNAs in cancer:origin, function and application. J Exp Clin Cancer Res, 2012, 31:38.
13.	Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol, 2008, 26(4):462-469.
14.	Ajit SK. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel), 2012, 12(3):3359-3369.
15.	Zhang C, Wang C, Chen X, et al. Expression profile of microRNAs in serum:a fingerprint for esophageal squamous cell carcinoma. Clin Chem, 2010, 56(12):1871-1879.
16.	Zhang T, Wang Q, Zhao D, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond), 2011, 121(10):437-447.
17.	Komatsu S, Ichikawa D, Takeshita H, et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer, 2011, 105(1):104-111.
18.	Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer, 2010, 102(7):1174-1179.
19.	Zhou H, Guo JM, Lou YR, et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med, 2010, 88(7):709-717.
20.	Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer, 2011, 47(5):784-791.
21.	Liu H, Zhu L, Liu B, et al. Genome-wide miRNAs profiles identify miRNA-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett, 2012, 316(2):196-203.
22.	Konishi H, Ichikawa D, Komatsu S, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma. Br J Cancer, 2012, 106(4):740-747.
23.	Song MY, Pan KF, Su HJ, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One, 2012, 7(3):e33608.
24.	Wang M, Gu H, Wang S, et al. Circulating miRNA-17-5p and miRNA-20a:molecular markers for gastric cancer. Mol Med Rep, 2012, 5(6):1514-1520.
25.	Valladares-Ayerbes M, Blanco M, Haz M, et al. Prognostic impactof disseminated tumor cells and microRNA-17-92 cluster deregula-tion in gastrointestinal cancer. Int J Oncol, 2011, 39(5):1253-1264.
26.	Katada T, Ishiguro H, Kuwabara Y, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol, 2009, 34(2):537-542.
27.	Jiang J, Zheng X, Xu X, et al. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS One, 2011, 6(8):e23271.
28.	Chen L, Jiang M, Yuan W, et al. Prognostic value of miR-93 overexpression in resectable gastric adenocarcinomas. Acta Gastroenterol Belg, 2012, 75(1):22-27.
29.	Inoue T, Iinuma H, Ogawa E, et al. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol Rep, 2012, 27(6):1759-1764.
30.	Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol, 2011, 17(35):3976-3985.
31.	Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer:a microRNA expression analysis. Lancet Oncol, 2010, 11(2):136-146.
32.	Liu K, Li G, Fan C, et al. Increased expression of microRNA-221 in gastric cancer and its clinical significance. J Int Med Res, 2012, 40(2):467-474.
33.	Zhang X, Yan Z, Zhang J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol, 2011, 22(10):2257-2266.
34.	Hashiguchi Y, Nishida N, Mimori K, et al. Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol, 2012, 40(5):1477-1482.
35.	Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res, 2011, 17(9):2725-2733.
36.	Kogo R, Mimori K, Tanaka F, et al. Clinical significance of miR-146ain gastric cancer cases. Clin Cancer Res, 2011, 17(13):4277-4284.
37.	Bandres E, Bitarte N, Arias F, et al. microRNA-451 regulates macro-phage migration inhibitory factor production and proliferation of the digestive tract cancer cells. Clin Cancer Res, 2009, 15(7):2281-2290.
38.	Wu WY, Xue XY, Chen ZJ, et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node. World J Gastroen-terol, 2011, 17(31):3645-3651.
39.	Tchernitsa O, Kasajima A, Schäfer R, et al. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol, 2010, 222(3):310-319.
40.	Motoyama K, Inoue H, Mimori K, et al. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol, 2010, 36(5):1089-1095.
41.	Ng EK, Chong WW, Jin H, et al. Differential expression of miRNAsin plasma of patients with colorectal cancer:a potential marker for colorectal cancer screening. Gut, 2009, 58(10):1375-1381.
42.	Huang Z, Huang D, Ni S, et al. Plasma miRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 2010, 127(1):118-126.
43.	Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol, 2012, 36(1):e61-e67.
44.	Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One, 2011, 6(3):e17745.
45.	Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol, 2010, 25(10):1674-1680.

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin, 2011, 61(2):69-90.
2. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer:a systematic review. Cancer Epidemiol Biomarkers Prev, 2007, 16(10):1935-1953.
3. Brennecke J, Stark A, Russell RB, et al. Principles of microRNA-target recognition. PLoS Biol, 2005, 3(3):e85.
4. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell, 2005, 120(1):15-20.
5. Marson A, Levine SS, Cole MF, et al. Connecting miRNAs genes to the core transcriptional regulatory circuitry of embryonic stem cells. Cell, 2008, 134(3):521-533.
6. Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol, 2008, 141(5):672-675.
7. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 2008, 105(30):10513-10518.
8. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum:a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 2008, 18(10):997-1006.
9. Mittra I, Nair NK, Mishra PK. Nucleic acids in circulation: are they harmful to the host?. J Biosci, 2012, 37(2):301-312.
10. Liang Y, Ridzon D, Wong L, et al. Characterization of microRNA expression profiles in normal human tissues. BMC Genomics, 2007, 8:166.
11. Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature, 2005, 435(7043):834-838.
12. Ma R, Jiang T, Kang XX. Circulating microRNAs in cancer:origin, function and application. J Exp Clin Cancer Res, 2012, 31:38.
13. Rosenfeld N, Aharonov R, Meiri E, et al. MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol, 2008, 26(4):462-469.
14. Ajit SK. Circulating microRNAs as biomarkers, therapeutic targets, and signaling molecules. Sensors (Basel), 2012, 12(3):3359-3369.
15. Zhang C, Wang C, Chen X, et al. Expression profile of microRNAs in serum:a fingerprint for esophageal squamous cell carcinoma. Clin Chem, 2010, 56(12):1871-1879.
16. Zhang T, Wang Q, Zhao D, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma. Clin Sci (Lond), 2011, 121(10):437-447.
17. Komatsu S, Ichikawa D, Takeshita H, et al. Circulating microRNAs in plasma of patients with oesophageal squamous cell carcinoma. Br J Cancer, 2011, 105(1):104-111.
18. Tsujiura M, Ichikawa D, Komatsu S, et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer, 2010, 102(7):1174-1179.
19. Zhou H, Guo JM, Lou YR, et al. Detection of circulating tumor cells in peripheral blood from patients with gastric cancer using microRNA as a marker. J Mol Med, 2010, 88(7):709-717.
20. Liu R, Zhang C, Hu Z, et al. A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer, 2011, 47(5):784-791.
21. Liu H, Zhu L, Liu B, et al. Genome-wide miRNAs profiles identify miRNA-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett, 2012, 316(2):196-203.
22. Konishi H, Ichikawa D, Komatsu S, et al. Detection of gastric cancer-associated microRNAs on microRNA microarray comparing pre-and post-operative plasma. Br J Cancer, 2012, 106(4):740-747.
23. Song MY, Pan KF, Su HJ, et al. Identification of serum microRNAs as novel non-invasive biomarkers for early detection of gastric cancer. PLoS One, 2012, 7(3):e33608.
24. Wang M, Gu H, Wang S, et al. Circulating miRNA-17-5p and miRNA-20a:molecular markers for gastric cancer. Mol Med Rep, 2012, 5(6):1514-1520.
25. Valladares-Ayerbes M, Blanco M, Haz M, et al. Prognostic impactof disseminated tumor cells and microRNA-17-92 cluster deregula-tion in gastrointestinal cancer. Int J Oncol, 2011, 39(5):1253-1264.
26. Katada T, Ishiguro H, Kuwabara Y, et al. microRNA expression profile in undifferentiated gastric cancer. Int J Oncol, 2009, 34(2):537-542.
27. Jiang J, Zheng X, Xu X, et al. Prognostic significance of miR-181b and miR-21 in gastric cancer patients treated with S-1/Oxaliplatin or Doxifluridine/Oxaliplatin. PLoS One, 2011, 6(8):e23271.
28. Chen L, Jiang M, Yuan W, et al. Prognostic value of miR-93 overexpression in resectable gastric adenocarcinomas. Acta Gastroenterol Belg, 2012, 75(1):22-27.
29. Inoue T, Iinuma H, Ogawa E, et al. Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer. Oncol Rep, 2012, 27(6):1759-1764.
30. Brenner B, Hoshen MB, Purim O, et al. MicroRNAs as a potential prognostic factor in gastric cancer. World J Gastroenterol, 2011, 17(35):3976-3985.
31. Ueda T, Volinia S, Okumura H, et al. Relation between microRNA expression and progression and prognosis of gastric cancer:a microRNA expression analysis. Lancet Oncol, 2010, 11(2):136-146.
32. Liu K, Li G, Fan C, et al. Increased expression of microRNA-221 in gastric cancer and its clinical significance. J Int Med Res, 2012, 40(2):467-474.
33. Zhang X, Yan Z, Zhang J, et al. Combination of hsa-miR-375 and hsa-miR-142-5p as a predictor for recurrence risk in gastric cancer patients following surgical resection. Ann Oncol, 2011, 22(10):2257-2266.
34. Hashiguchi Y, Nishida N, Mimori K, et al. Down-regulation of miR-125a-3p in human gastric cancer and its clinicopathological significance. Int J Oncol, 2012, 40(5):1477-1482.
35. Nishida N, Mimori K, Fabbri M, et al. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab. Clin Cancer Res, 2011, 17(9):2725-2733.
36. Kogo R, Mimori K, Tanaka F, et al. Clinical significance of miR-146ain gastric cancer cases. Clin Cancer Res, 2011, 17(13):4277-4284.
37. Bandres E, Bitarte N, Arias F, et al. microRNA-451 regulates macro-phage migration inhibitory factor production and proliferation of the digestive tract cancer cells. Clin Cancer Res, 2009, 15(7):2281-2290.
38. Wu WY, Xue XY, Chen ZJ, et al. Potentially predictive microRNAs of gastric cancer with metastasis to lymph node. World J Gastroen-terol, 2011, 17(31):3645-3651.
39. Tchernitsa O, Kasajima A, Schäfer R, et al. Systematic evaluation of the miRNA-ome and its downstream effects on mRNA expression identifies gastric cancer progression. J Pathol, 2010, 222(3):310-319.
40. Motoyama K, Inoue H, Mimori K, et al. Clinicopathological and prognostic significance of PDCD4 and microRNA-21 in human gastric cancer. Int J Oncol, 2010, 36(5):1089-1095.
41. Ng EK, Chong WW, Jin H, et al. Differential expression of miRNAsin plasma of patients with colorectal cancer:a potential marker for colorectal cancer screening. Gut, 2009, 58(10):1375-1381.
42. Huang Z, Huang D, Ni S, et al. Plasma miRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 2010, 127(1):118-126.
43. Wang LG, Gu J. Serum microRNA-29a is a promising novel marker for early detection of colorectal liver metastasis. Cancer Epidemiol, 2012, 36(1):e61-e67.
44. Cheng H, Zhang L, Cogdell DE, et al. Circulating plasma miR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One, 2011, 6(3):e17745.
45. Pu XX, Huang GL, Guo HQ, et al. Circulating miR-221 directly amplified from plasma is a potential diagnostic and prognostic marker of colorectal cancer and is correlated with p53 expression. J Gastroenterol Hepatol, 2010, 25(10):1674-1680.

Previous Article
Research Progress of Relationship Between CSN and Malignant Tumor
Next Article
Therapeutic Targets of Pancreatic Cancer

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Molecular Microsensors in The Digestive Tract Cancer: Circulating MicroRNAs

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content